Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HORIZON-PFT: Pivotal Fracture Trial.

Next Previous
X
Search
Trial Profile

HORIZON-PFT: Pivotal Fracture Trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Hip fracture; Postmenopausal osteoporosis; Vertebral fracture
  • Focus Registrational; Therapeutic Use
  • Acronyms HORIZON-PFT
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 16 Oct 2012 Extension study results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
    • 01 Aug 2012 Results published in the Journal of Bone and Mineral Research.
    • 24 Mar 2012 Results assessing renal function presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top